LAB282 is a new funding partnership in Oxford, which has just awarded its first grants. We interviewed Dr Thomas Hanke, Expert in Residence at LAB282 and Head of Academic Partnerships at Evotec. Read on to find out what is so unique about LAB282, what it can offer and, most importantly, how to get them toaaa

Fostering Pharma collaborations, securing grants for innovation and investment opportunities to innovate in the University setting The University of Oxford 2013-2018 strategic plan starts with the vision to lead in research and education and foster a culture in which innovation plays an important role, with the ultimate goal to benefit society on a national andaaa

Oxford University and Evotec’s drug discovery partnership launched last November to accelerate drugs to market begins making awards. Hamburg, Germany, 21 February 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) is pleased to announce that LAB282, the £13m drug discovery partnership with Oxford University, has made its first wave of awards, backing projectsaaa